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Abstract: The impact of nutritional status on HTx waitlist mortality in
children is unknown, and there are conﬂicting data regarding the role
of nutrition in post-HTx survival. This study examined the inﬂuence of
nutrition on waitlist and post-HTx outcomes in children. Children
2–18 yr listed for HTx from 1997 to 2011 were identiﬁed from the
OPTN database and stratiﬁed by BMI percentile. Multivariable logistic
regression evaluated the inﬂuence of BMI on waitlist mortality. Cox
proportional hazard regression assessed the impact of BMI on post-
HTx mortality. When all 2712 patients were analyzed, BMI did not
impact waitlist, one-, or ﬁve-yr mortality. However, when stratiﬁed by
diagnosis, BMI > 95% (AOR 1.96; 95% CI 1.24, 3.09) and BMI < 1%
(AOR 2.17; 95% CI 1.28, 3.68) were independent risk factors for
waitlist mortality in patients with CM. BMI did not impact waitlist
mortality in CHD and did not impact post-HTx outcomes, regardless
of diagnosis. BMI > 95% and BMI < 1% are independent risk factors
for waitlist mortality in patients with CM, but not CHD. This suggests
diﬀering risk factors based on disease etiology, and an individualized
approach to risk assessment based on diagnosis may be warranted.
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Nutritional status has recently been identiﬁed as
an independent risk factor for waitlist mortality
in infants awaiting HTx (1); however, it is
unknown if pre-HTx nutrition impacts waitlist
survival in older pediatric patients. Additionally,
there are conﬂicting data regarding the impact of
pre-HTx nutrition on post-HTx survival in pedi-
atric patients (2–5), despite adult data indicating
decreased survival in the setting of wasting or
obesity (6, 7). Furthermore, recent studies have dem-
onstrated that risk factors for non-survival following
pediatric HTx diﬀer based on heart disease etiology
(8, 9), but nutritionwasnot rigorously studied in those
analyses. This study aimed to assess (i) the impact of
pre-HTxnutritiononwaitlist andpost-HTxoutcomes
in patients aged 2–18 yr and (ii) determine whether
the risk conferred by suboptimal nutritional status dif-
fered based onpre-HTxdiagnosis.
Methods
This is a retrospective cohort study utilizing the OPTN
database.
Patient selection and data collection
The OPTN database was queried for all patients aged
2–18 yr listed for HTx in the United States between 1997
and 2011. BMI percentile was calculated at the time of
listing for each patient, and nutritional groups were classiﬁed
as follows: obese (BMI > 95%), overweight (BMI 85–95%),
normal (BMI 5–85%), underweight (BMI 1–5%), and
severely wasted (BMI < 1%). Because exact ages are not
available in the OPTN data, BMI percentiles were calculated
at the half-year mark for each patient to minimize error.
Patients were excluded from analysis if they underwent a
prior transplant, underwent a non-orthotopic HTx, weight
or height was missing, or if they failed to meet an outcome
while on the waitlist (death or HTx). Also, to minimize error
Abbreviations: AHR, adjusted hazard ratio; AOR,
adjusted odds ratio; BMI, body mass index; CHD, congeni-
tal heart disease; CI, conﬁdence interval; CM, cardiomyop-
athy; ECMO, extracorporeal membrane oxygenation; HTx,
heart transplant; IBW, ideal body weight; OPTN, Organ
Procurement and Transplantation Network; Ref, reference
category; VAD, ventricular assist device.
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due to spurious values, patients were excluded if they had a
decrease in height between listing and transplant of >5 cm,
or a markedly abnormal BMI z-score (>6 or <6). Addi-
tional variables collected for analysis included gender, race,
blood type, age at listing, status at listing (1A, 1B, or 2),
diagnosis (CHD, CM, or other), waitlist time, ventilator use,
ECMO requirement, VAD support, inotrope use, and infec-
tions requiring IV drug therapy within two wk of listing.
Following analysis of the entire study cohort, the cohort was
stratiﬁed into two groups by diagnosis (CM or CHD) and
the analysis was repeated. Patients with a diagnosis of
“other” were excluded when the cohort was stratiﬁed. The
primary outcomes were (i) waitlist mortality, (ii) post-HTx
mortality at one yr, and (iii) post-HTx mortality at ﬁve yr.
Statistical methods
Demographics and patient characteristics between survivors
and non-survivors were compared using the chi-square test
or Fisher’s exact test for categorical variables and Wilcoxon
rank sum test for continuous variables. Risk factors associ-
ated with waitlist mortality were assessed using logistic
regression, and factors associated with one- and ﬁve-yr post-
HTx mortality were assessed using Cox proportional hazard
models. Variables found to be signiﬁcantly associated with
waitlist or post-HTx mortality on univariate analysis
(p < 0.1) were adjusted for in the multivariable regression
models to determine independent associations of pre-HTx
nutrition with outcomes. All analyses were performed using
SAS version 9.3 (SAS Institute Inc, Cary, NC, USA).
Results
Of 3031 patients listed for HTx during the study
period, 2712 were included in the analysis. Of the
patients excluded from analysis, 86 (2.8%) were
removed from the waitlist due to clinical deterio-
ration. Nutritional status in this group was not
signiﬁcantly diﬀerent compared with those who
underwent HTx or who died on the waitlist
(p = 0.29 from chi-square test). Baseline patient
characteristics are shown in Table 1. At listing,
354 (13%) patients were obese, 284 (10%) were
overweight, 1598 (59%) were normal, 210 (8%)
were underweight, and 266 (10%) were severely
wasted. Of the patients included in the study,
2345 (86%) survived to HTx, while 367 (14%)
died on the waitlist. When the entire study cohort
was analyzed, nutrition at listing was not associ-
ated with waitlist mortality after adjusting for
race, blood type, age at listing, status at listing, diag-
nosis, ventilator requirement, ECMO or VAD sup-
port, inotrope use, and nutritional status (Table 2).
Of the patients who underwent HTx, 2129 (91%)
survived one yr and 1869 (80%) survived ﬁve yr
post-HTx.Nutritional status at listing had no impact
on one- or ﬁve-yr post-HTx mortality after control-
ling for gender, race, diagnosis, age at listing, status
at listing, and the need for ECMOsupport (Table 3).
There were 1662 patients (61%) with a diagno-
sis of CM. Of these patients, 256 (15%) were
obese, 189 (11%) were overweight, 944 (57%)
were normal, 122 (7%) were underweight, and
151 (9%) were severely wasted. A total of 1490
patients (90%) with CM underwent HTx and 172
(10%) died on the waitlist. Both obesity (AOR
1.96; 95% CI 1.24, 3.09) and severe wasting
(AOR 2.17; 95% CI 1.28, 3.68) were independent
risk factors for waitlist mortality in this group
after adjusting for blood type, age at listing, sta-
tus at listing, ventilator requirement, and ECMO
or VAD support (Table 4). Of those who under-
went HTx, 1387 (93%) survived one yr and 1225
(82%) survived ﬁve yr post-HTx. Nutrition was
not a risk factor for one- or ﬁve-yr post-HTx
mortality in this group when controlling for gen-
der, race, diagnosis (dilated CM, restrictive CM,
or hypertrophic CM), and age at listing (Table 5).
To exclude an era eﬀect leading to these ﬁndings,
a secondary analysis was performed using a more
contemporary cohort (2002–2011). Severe wast-
ing remained an independent risk factor for
waitlist mortality with borderline signiﬁcance
(p = 0.05); however, obesity no longer appeared
as a signiﬁcant risk factor for waitlist mortality.
Of 975 (36%) patients with a diagnosis of
CHD, 89 (9%) were obese, 82 (8%) were over-
weight, 608 (62%) were normal, 85 (9%) were
underweight, and 111 (11%) were severely
wasted. A total of 800 (82%) patients with CHD
underwent HTx and 175 (18%) died on the wait-
list. In this group, nutritional status at listing was
not associated with waitlist mortality after adjust-
ing for race, blood type, status at listing, ventila-
tor support, and inotrope use (Table 4). Of those
who underwent HTx, 694 (87%) survived to
one yr and 600 (75%) survived to ﬁve yr post-
HTx. Nutrition was not a risk factor for one- or
ﬁve-yr post-HTx mortality when controlling for
race and the need for ECMO support (Table 5).
Due to previous data suggesting that percent
IBW may be a better predictor of morbidity and
mortality following HTx in adult recipients than
BMI (6), a secondary analysis was performed
using IBW in lieu of BMI to stratify the cohort. This
analysis resulted in similar ﬁndings that both obesity
(IBW > 140%) (AOR 2.03; 95% CI 1.26, 3.29) and
severe wasting (IBW < 80%) (AOR 2.18; 95% CI
1.25, 3.80) were independent risk factors for waitlist
mortality in patients withCM, but not CHD.
Additionally, it is known that some transplant
centers view elevated BMI as a contraindication
to HTx; however, there are little data to support
this strategy. To address this, a secondary analy-
sis was performed comparing waitlist and
post-HTx outcomes of adolescent patients (ages
13–18) with BMI > 35 (N = 34) to those with a
BMI in the normal range (18.5 ≤ BMI < 25)
(N = 474). No diﬀerence in waitlist, one-, or ﬁve-
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yr mortality was found between these groups;
however, the analysis was limited by a small
number of patients.
Discussion
This study provides new insight into the role that
pre-HTx nutrition plays in waitlist and post-HTx
survival in pediatric patients, and it demonstrates
that pre-HTx diagnosis modiﬁes the risk con-
ferred by abnormal nutrition in children. The
extremes of nutrition, either obesity or severe
wasting, are associated with an increased risk of
waitlist mortality in pediatric patients with CM
awaiting HTx. Interestingly, this ﬁnding did not
hold true in patients with a diagnosis of CHD, or
Table 1. Pre-transplant characteristics in patients aged 2–18 yr who underwent their first orthotopic HTx in the United States in the past 15 yr (N = 2712)
Characteristics Overall
Survival to transplant
p-Value*Yes (N = 2345) No (N = 367)
Female sex 1119 (41.3) 970 (41.4) 149 (40.6) 0.78
Race
Caucasian 1510 (55.7) 1325 (56.5) 185 (50.4) 0.16
African American 610 (22.5) 516 (22.0) 94 (25.6)
Hispanic 395 (14.6) 334 (14.2) 61 (16.6)
Other 197 (7.3) 170 (7.2) 27 (7.4)
Blood type
A 992 (36.6) 902 (38.5) 90 (24.5) <0.0001
B 340 (12.5) 301 (12.8) 39 (10.6)
O 1272 (46.9) 1043 (44.5) 229 (62.4)
AB 108 (4.0) 99 (4.2) 9 (2.5)
Age at listing, yr 11 (6–15) 12 (6–15) 10 (4–15) 0.01
<4 yr 405 (14.9) 325 (13.9) 80 (21.8) 0.0004
4–12 yr 1116 (41.2) 975 (41.6) 141 (38.4)
13–18 yr 1191 (43.9) 1045 (44.6) 146 (39.8)
Status at listing
1 or 1A 1,406 (51.8) 1,173 (50.0) 233 (63.5) <0.0001
1B 370 (13.6) 327 (13.9) 43 (11.7)
2 905 (33.4) 818 (34.9) 87 (23.7)
Temporarily inactive or unknown 31 (1.1) 27 (1.2) 4 (1.1)
Diagnosis at listing
Cardiomyopathy 1,662 (61.3) 1,490 (63.5) 172 (46.9) <0.0001†
Dilated cardiomyopathy 1,364 (50.3) 1,214 (51.8) 150 (40.9)
Restrictive cardiomyopathy 225 (8.3) 209 (8.9) 16 (4.4)
Hypertrophic cardiomyopathy 73 (2.7) 67 (2.9) 6 (1.6)
Congenital heart defect 975 (36.0) 800 (34.1) 175 (47.7)
Other 75 (2.8) 55 (2.3) 20 (5.4)
Waiting time, days 40 (15–104) 41 (14–104) 34 (15–109) 0.90
<30 days 1,127 (41.6) 963 (41.1) 164 (44.7) 0.19
≥30 days 1,585 (58.4) 1,382 (58.9) 203 (55.3)
Nutritional status at listing‡ 0.16
Obese 354 (13.1) 300 (12.8) 54 (14.7) 0.25§
Overweight 284 (10.5) 248 (10.6) 36 (9.8) 0.90§
Normal 1,598 (58.9) 1,391 (59.3) 207 (56.4) Ref
Underweight 210 (7.7) 187 (8.0) 23 (6.3) 0.41§
Severely wasted 266 (9.8) 219 (9.3) 47 (12.8) 0.04§
Use of ventilator at listing 313 (11.5) 212 (9.0) 101 (27.5) <0.0001
ECMO support at listing 137 (5.1) 95 (4.1) 42 (11.4) <0.0001
Inotrope use at listing 1,276 (47.1) 1,072 (45.7) 204 (55.6) 0.0004
Use of VAD at listing 403 (14.9) 372 (15.9) 31 (8.4) 0.0002
Infection requiring IV drug therapy
(within two wk of listing)
126 (4.6) 106 (4.5) 20 (5.4) 0.01
*p-Value from chi-square tests for categorical variables and Wilcoxon rank sum test for continuous variable on comparison of each characteristic between the
patients who survived to transplant and those who did not.
†Comparison was made between cardiomyopathy vs. congenital heart defect vs. others (p-value from chi-square test).
‡Nutritional status defined as severely wasted if BMI < 1st percentile, underweight if BMI 1st–5th percentile, overweight if BMI 85–95th percentile, obese if
BMI > 95th percentile, and normal if otherwise.
§p-value from pairwise comparison between each abnormal nutritional status and normal.
Data are presented as N (%) for categorical variables and median (25–75th percentile) for continuous variables.
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when the entire cohort was analyzed together.
The explanation for this apparent diﬀerence in
risk conferred by abnormal nutrition is not
entirely clear.
Published studies directly evaluating diﬀer-
ences in risk factors between patients with CM
and CHD are lacking. A recent pediatric HTx
study analysis assessed post-HTx outcomes in
each of these populations and demonstrated that
risk proﬁles vary based on heart disease etiology
(8, 9). Our study provides additional evidence that
risk factors are modiﬁed by disease etiology and
an individualized approach to risk factor assess-
ment based on diagnosis may be warranted.
There are limited and conﬂicting data regard-
ing the eﬀect of nutrition on pediatric HTx out-
comes (2–5). Single center studies have
concluded that BMI < 5th percentile (2) and
Table 3. Hazard ratios of non-survival at one and five yr post-transplant
based on pre-transplant nutrition in all patients aged 2–18 yr who underwent
their first orthotopic HTx in the United States in the past 15 yr (N = 2345)
Characteristics AHR 95% CI p-Value*
One-yr non-survival based
on nutritional status at listing†
0.73
Obese 1.16 0.76, 1.75 0.49
Overweight 1.33 0.88, 2.00 0.18
Normal Ref
Underweight 1.03 0.62, 1.72 0.90
Severely wasted 1.11 0.71, 1.76 0.64
Five-yr non-survival based
on nutritional status at listing†
0.54
Obese 1.10 0.84, 1.46 0.49
Overweight 1.27 0.96, 1.68 0.10
Normal Ref
Underweight 0.97 0.69, 1.37 0.88
Severely wasted 1.01 0.73, 1.38 0.97
*p-Value from multivariable Cox proportional hazard model.
†Nutritional status defined as severely wasted if BMI < 1st percentile, under-
weight if BMI 1st–5th percentile, overweight if BMI 85–95th percentile, obese
if BMI > 95th percentile, and normal if otherwise.
Table 2. Odds of non-survival to transplant based on pre-transplant nutrition
in all patients aged 2–18 yr who underwent their first orthotopic HTx in the
United States in the past 15 yr (N = 2712)
Characteristics AOR 95% CI p-Value*
Nutritional status at listing† 0.33
Obese 1.29 0.91, 1.83 0.15
Overweight 1.00 0.67, 1.49 0.99
Normal Ref
Underweight 0.81 0.50, 1.30 0.38
Severely wasted 1.27 0.87, 1.85 0.22
*p-Value from multivariable logistic regression.
†Nutritional status defined as severely wasted if BMI < 1st percentile, under-
weight if BMI 1st–5th percentile, overweight if BMI 85–95th percentile, obese
if BMI > 95th percentile, and normal if otherwise.
Table 4. Odds of non-survival to transplant based on pre-transplant nutrition
in patients with CM (N = 1662) and CHD (N = 975)
Characteristics AOR 95% CI p-Value*
Cardiomyopathy
Nutritional status at listing† 0.01
Obese 1.96 1.24, 3.09 0.004
Overweight 1.56 0.91, 2.68 0.10
Normal Ref
Underweight 1.03 0.52, 2.02 0.94
Severely wasted 2.17 1.28, 3.68 0.004
Congenital heart disease
Nutritional status at listing† 0.89
Obese 0.89 0.49, 1.64 0.72
Overweight 0.79 0.41, 1.51 0.47
Normal Ref
Underweight 0.77 0.39, 1.53 0.65
Severely wasted 0.88 0.51, 1.52 0.45
*p-Value from multivariable logistic regression.
†Nutritional status defined as severely wasted if BMI < 1st percentile, under-
weight if BMI 1st–5th percentile, overweight if BMI 85–95th percentile, obese
if BMI > 95th percentile, and normal if otherwise.
Table 5. Hazard ratios of non-survival at one and five yr post-transplant
based on pre-transplant nutrition in patients with CM (N = 1490) and CHD
(N = 800)
Characteristics AHR 95% CI p-Value*
Cardiomyopathy
One-yr non-survival based on
nutritional status at listing†
0.62
Obese 1.32 0.76, 2.31 0.32
Overweight 1.44 0.81, 2.56 0.22
Normal Ref
Underweight 1.29 0.61, 2.71 0.51
Severely wasted 1.44 0.73, 2.84 0.29
Five-yr non-survival based on
nutritional status at listing†
0.51
Obese 1.22 0.87, 1.71 0.25
Overweight 1.32 0.92, 1.89 0.13
Normal Ref
Underweight 1.08 0.66, 1.77 0.77
Severely wasted 1.22 0.77, 1.94 0.39
Congenital heart disease
One-yr non-survival based on
nutritional status at listing†
0.97
Obese 1.09 0.57, 2.07 0.79
Overweight 1.05 0.54, 2.06 0.88
Normal Ref
Underweight 0.79 0.38, 1.64 0.52
Severely wasted 0.99 0.54, 1.84 0.99
Five-yr non-survival based on
nutritional status at listing†
0.98
Obese 0.89 0.54, 1.48 0.66
Overweight 1.03 0.62, 1.71 0.91
Normal Ref
Underweight 0.89 0.54, 1.46 0.65
Severely wasted 0.95 0.60, 1.49 0.81
*p-Value from multivariable Cox proportional hazard model.
†Nutritional status defined as severely wasted if BMI < 1st percentile, under-
weight if BMI 1st–5th percentile, overweight if BMI 85–95th percentile, obese
if BMI > 95th percentile, and normal if otherwise.
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obesity (3) are associated with decreased post-
HTx survival. These ﬁndings are consistent with
studies among adult HTx recipients, where pre-
HTx cachexia and obesity have been associated
with worse post-HTx outcomes (6, 7). In contrast
to these ﬁndings, an analysis of the International
Society for Heart and Lung Transplantation
database demonstrated no correlation between
nutritional status and post-HTx outcomes in
children (4). Nutritional status has also been
shown to inﬂuence waitlist outcomes for children
<two yr of age, with both moderate/severe wast-
ing and elevated weight-to-height ratio being
associated with an increased risk of waitlist mor-
tality (1). None of these previous studies assessed
the impact of nutrition stratiﬁed by diagnosis,
and our unique ﬁnding that the risk imparted by
abnormal nutrition is modiﬁed by pre-HTx diag-
nosis has not previously been reported.
There are several potential explanations for
the varying impact of nutrition on waitlist mor-
tality based on pre-HTx diagnosis. Patients with
CHD in this cohort experienced a higher waitlist
mortality (18%) compared with patients with
CM (10%), which is consistent with prior reports
that CHD is an independent risk factor for wait-
list death (10). The factors contributing to this
increased waitlist mortality in CHD may out-
weigh any added risk conferred by abnormal
nutrition. Additionally, the indications for HTx
vary between patients with CM and CHD. The
CM group in our study consisted primarily of
patients with dilated CM, in whom systolic dys-
function is the most likely indication for HTx,
and may in fact predispose these patients to mal-
nutrition (11–13). While systolic dysfunction
may also prompt consideration of HTx in
patients with CHD, the indications for HTx in
this group are much more heterogeneous. The
most common indications for HTx in patients
with CHD outside of the newborn period are
failed single ventricle palliation and those with a
systemic right ventricle (14, 15). Heart failure in
these groups may not be manifest as isolated sys-
tolic dysfunction and instead may be secondary
to pulmonary hypertension, arrhythmias, ele-
vated venous pressures, or signiﬁcant atrioven-
tricular valve regurgitation. Piran and colleagues
reported higher rates of cyanosis and arrhyth-
mias in adult patients with CHD and symptom-
atic heart failure (16). This represents a distinctly
diﬀerent pathophysiology than systolic dysfunc-
tion, which may not be as susceptible to nutri-
tional eﬀects. Additionally, the etiology of
wasting may be diﬀerent between patients with
CHD and CM, and there is evidence that cyano-
sis and pulmonary hypertension may play an
important role in the development of growth
failure in patients with CHD (17).
Optimizing nutritional status may play a role
in improving survival to HTx in patients with
CM; however, the best way to achieve this is
unknown. Adequate caloric intake in patients
with signiﬁcant heart failure may be diﬃcult to
attain (18), and poor growth has been demon-
strated, despite aggressive enteral nutritional
support (19). Signiﬁcant heart failure may lead
to wasting and preclude an anabolic state regard-
less of nutritional intervention (1, 19). Aggressive
support with enteral and/or parenteral nutrition
may be warranted, and early involvement of a
dietician as part of the multidisciplinary team
may be beneﬁcial. For patients with CM and
growth failure refractory to medical intervention,
consideration of VAD placement or earlier list-
ing for HTx may improve waitlist survival (1).
Further research is required to outline the opti-
mal support strategies for these patients and to
determine whether improvement in pre-HTx
BMI mitigates the risk of waitlist death.
The secondary analyses performed suggest
that era may have impacted the role of nutrition
in HTx outcomes. The more contemporary
cohort includes a time when pediatric VAD use
was increasing; however, the inclusion of VAD
requirement in the multivariable analysis makes
it unlikely that this change in practice inﬂuenced
this result. Regardless of era, severe wasting
remained an independent risk factor for waitlist
mortality in patients with CM, but not CHD.
Obesity, however, was not a risk factor for
waitlist mortality in the more recent era. The sig-
niﬁcance of this change is unclear; era-based
practice change may reduce the inﬂuence of
obesity on poor outcome in these patients.
Alternatively, signiﬁcant analytic power was lost
when assessing the more contemporary cohort,
which could also explain the loss of obesity as an
independent risk factor. Further assessment of
obesity as a risk factor is warranted in future
analyses. Additionally, these data do not support
a strategy to use signiﬁcantly elevated BMI as a
contraindication to listing for HTx given that no
signiﬁcant diﬀerences were found in waitlist or
post-HTx mortality. However, this analysis was
limited by small patient numbers and therefore
warrants further study.
Limitations
There are several limitations to this study. The
OPTN database precludes a detailed analysis
due to lack of data granularity. Also, data
may be missing or erroneous, and it is not
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possible to retrospectively assure accuracy of
the data provided, despite attempts to limit
inclusion of erroneous data. Because exact
ages are unavailable in the OPTN data, BMI
percentiles were calculated at the half-year
mark for each patient. The half-year mark was
chosen in an attempt to minimize error, but
some degree of error was unavoidable. Also,
BMI does not account for ﬂuid overload. This
could lead to misclassiﬁcation of patients with
signiﬁcant edema.
Conclusion
Severe wasting and obesity are independent risk
factors for waitlist mortality in pediatric patients
with CM, but not those with CHD. Further
investigation is required to determine whether
optimizing pre-HTx nutritional status can
improve HTx outcomes. Abnormal pre-HTx
nutritional status should not inﬂuence the deci-
sion to list for HTx, given equivalent post-HTx
outcomes in all groups. Future studies assessing
risk factors should consider stratifying analyses
based on diagnoses to avoid overlooking poten-
tially important ﬁndings.
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